BioMarin Pharmaceutical Inc, 770 Lindaro Street, San Rafael, CA, 94901, USA.
RTI Health Solutions, Barcelona, Av. Diagonal 605, 9-4, 08028, Barcelona, Spain.
Orphanet J Rare Dis. 2021 Jun 3;16(1):253. doi: 10.1186/s13023-021-01874-6.
Phenylalanine hydroxylase (PAH) deficiency is an autosomal recessive disorder that results in elevated concentrations of phenylalanine (Phe) in the blood. If left untreated, the accumulation of Phe can result in profound neurocognitive disability. The objective of this systematic literature review and meta-analysis was to estimate the global birth prevalence of PAH deficiency from newborn screening studies and to estimate regional differences, overall and for various clinically relevant Phe cutoff values used in confirmatory testing.
The protocol for this literature review was registered with PROSPERO (International prospective register of systematic reviews). Pubmed and Embase database searches were used to identify studies that reported the birth prevalence of PAH deficiency. Only studies including numeric birth prevalence reports of confirmed PAH deficiency were included.
From the 85 publications included in the review, 238 birth prevalence estimates were extracted. After excluding prevalence estimates that did not meet quality assessment criteria or because of temporal and regional overlap, estimates from 45 publications were included in the meta-analysis. The global birth prevalence of PAH deficiency, estimated by weighting regional birth prevalences relative to their share of the population of all regions included in the study, was 0.64 (95% confidence interval [CI] 0.53-0.75) per 10,000 births and ranged from 0.03 (95% CI 0.02-0.05) per 10,000 births in Southeast Asia to 1.18 (95% CI 0.64-1.87) per 10,000 births in the Middle East/North Africa. Regionally weighted global birth prevalences per 10,000 births by confirmatory test Phe cutoff values were 0.96 (95% CI 0.50-1.42) for the Phe cutoff value of 360 ± 100 µmol/L; 0.50 (95% CI 0.37-0.64) for the Phe cutoff value of 600 ± 100 µmol/L; and 0.30 (95% CI 0.20-0.40) for the Phe cutoff value of 1200 ± 200 µmol/L.
Substantial regional variation in the birth prevalence of PAH deficiency was observed in this systematic literature review and meta-analysis of published evidence from newborn screening. The precision of the prevalence estimates is limited by relatively small sample sizes, despite widespread and longstanding newborn screening in much of the world.
苯丙氨酸羟化酶(PAH)缺乏症是一种常染色体隐性疾病,导致血液中苯丙氨酸(Phe)浓度升高。如果不治疗,Phe 的积累会导致严重的神经认知障碍。本系统文献综述和荟萃分析的目的是从新生儿筛查研究中估计 PAH 缺乏症的全球出生流行率,并估计区域差异、整体差异以及在确认性检测中使用的各种临床相关 Phe 截止值的差异。
本文献综述的方案已在 PROSPERO(国际前瞻性系统评价注册库)中注册。使用 Pubmed 和 Embase 数据库搜索来确定报告 PAH 缺乏症出生流行率的研究。仅纳入了报告经确认的 PAH 缺乏症的出生流行率的研究。
从综述中纳入的 85 篇文献中,提取了 238 项出生流行率估计值。排除不符合质量评估标准的流行率估计值,或因时间和区域重叠而排除的流行率估计值后,有 45 篇文献的估计值纳入荟萃分析。根据研究中所有地区的人口比例对区域出生流行率进行加权,全球 PAH 缺乏症的出生流行率估计值为每 10000 例出生 0.64(95%置信区间[CI] 0.53-0.75),范围从东南亚的每 10000 例出生 0.03(95% CI 0.02-0.05)到中东/北非的每 10000 例出生 1.18(95% CI 0.64-1.87)。按确认性检测 Phe 截止值为 360±100 μmol/L、600±100 μmol/L 和 1200±200 μmol/L 时,每 10000 例出生的加权全球出生流行率分别为 0.96(95% CI 0.50-1.42)、0.50(95% CI 0.37-0.64)和 0.30(95% CI 0.20-0.40)。
本系统文献综述和荟萃分析发现,在新生儿筛查中发表的证据中,PAH 缺乏症的出生流行率存在显著的区域差异。尽管在世界大部分地区已经广泛和长期进行新生儿筛查,但由于样本量相对较小,流行率估计的准确性受到限制。